Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Treatments: Lurasidone Hydrochloride

Criteria

Inclusion Criteria:

• Patients who are considered by the investigator eligible for the present study with no significant safety concerns

• Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patients who are planning pregnancy for the expected duration of the study

• Patients who are otherwise considered ineligible for the study by the investigator